Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life setting

Saved in:
Bibliographic Details
Main Authors: I. Ciobotariu, A. Di Stefani, A. Paradisi, L. Di Nardo, K. Peris
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:EJC Skin Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2772611824002246
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846159034912079872
author I. Ciobotariu
A. Di Stefani
A. Paradisi
L. Di Nardo
K. Peris
author_facet I. Ciobotariu
A. Di Stefani
A. Paradisi
L. Di Nardo
K. Peris
author_sort I. Ciobotariu
collection DOAJ
format Article
id doaj-art-7a19caa3df7a4a3ba94e980e1f3d009a
institution Kabale University
issn 2772-6118
language English
publishDate 2024-01-01
publisher Elsevier
record_format Article
series EJC Skin Cancer
spelling doaj-art-7a19caa3df7a4a3ba94e980e1f3d009a2024-11-24T04:15:21ZengElsevierEJC Skin Cancer2772-61182024-01-012100236Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life settingI. Ciobotariu0A. Di Stefani1A. Paradisi2L. Di Nardo3K. Peris4Fondazione Policlinico Universitario A. Gemelli - IRCCS, UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Rome, ItalyFondazione Policlinico Universitario A. Gemelli - IRCCS, UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Rome, ItalyFondazione Policlinico Universitario A. Gemelli - IRCCS, UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Rome, ItalyFondazione Policlinico Universitario A. Gemelli - IRCCS, UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Rome, ItalyFondazione Policlinico Universitario A. Gemelli - IRCCS, UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italyhttp://www.sciencedirect.com/science/article/pii/S2772611824002246
spellingShingle I. Ciobotariu
A. Di Stefani
A. Paradisi
L. Di Nardo
K. Peris
Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life setting
EJC Skin Cancer
title Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life setting
title_full Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life setting
title_fullStr Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life setting
title_full_unstemmed Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life setting
title_short Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life setting
title_sort neutrophil lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to cemiplimab treatment a real life setting
url http://www.sciencedirect.com/science/article/pii/S2772611824002246
work_keys_str_mv AT iciobotariu neutrophillymphocyteratioasapredictivemarkerforprogressionfreesurvivalinpatientswithadvancedcutaneoussquamouscellcarcinomapriortocemiplimabtreatmentareallifesetting
AT adistefani neutrophillymphocyteratioasapredictivemarkerforprogressionfreesurvivalinpatientswithadvancedcutaneoussquamouscellcarcinomapriortocemiplimabtreatmentareallifesetting
AT aparadisi neutrophillymphocyteratioasapredictivemarkerforprogressionfreesurvivalinpatientswithadvancedcutaneoussquamouscellcarcinomapriortocemiplimabtreatmentareallifesetting
AT ldinardo neutrophillymphocyteratioasapredictivemarkerforprogressionfreesurvivalinpatientswithadvancedcutaneoussquamouscellcarcinomapriortocemiplimabtreatmentareallifesetting
AT kperis neutrophillymphocyteratioasapredictivemarkerforprogressionfreesurvivalinpatientswithadvancedcutaneoussquamouscellcarcinomapriortocemiplimabtreatmentareallifesetting